Drug Approval | February 10, 2025
During the quarter, US formulations revenue decreased by 2.3% YoY to Rs. 3,671 crore.
Plans underway to expand screening capacity by 50% for greater accessibility
Itolizumab achieved key secondary endpoint of endoscopic remission of 16.7% compared to 16.7% for adalimumab and 6.7% for placebo
Cancer cases in India estimated to reach 1.57 million in 2025
The company anticipates 2025 worldwide sales to be between $64.1 billion and $65.6 billion
Profit after Taxes registered strong growth of 22% to Rs. 162 crores versus Rs. 134 crores in Q3 FY24
International Meeting of World Pharmacopoeias serves as a vital platform to foster international collaboration in pharmacopoeial science and regulatory harmonization
These results represent critical milestones for Philogen, as Fibromun has the potential to become second product to successfully complete multinational clinical trials with registration potential
This innovative formulation combines cutting-edge ingredients is a first of its kind in India to have a Duo-Lipo technology
Subscribe To Our Newsletter & Stay Updated
